SAKK 16/18: QA and Interim Safety of Immune-Modulatory RT in Resectable Stage III(N2) NSCLC
Tobias Finazzi,Lisa Holer, Hongjian Tang,Oliver Riesterer,Abdelkarim Allal,Olgun Elicin,Markus Glatzer, Andre Durham,Francesco Martucci,Lukas Adam, Katarzyna Mosna-Firlejczyk,Adrienne Bettini,David Konig,Simon Haefliger,Martin Fruh,Wolf-Dieter Janthur, Alfredo Addeo,Patrizia Froesch,Michael Mark, Bernhard Scheibe,Patrick Dorn,Spasenija Savic Prince,Sacha I. Rothschild,Matthias Guckenberger,Laetitia A. Mauti RADIOTHERAPY AND ONCOLOGY(2024)
Key words
NSCLC,Immunotherapy,Stage III
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper